Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial.

Inclusion Criteria: * Both genres. * Age between 18 and 75 years. * Clinical diagnosis of toxic optic neuropathy (afferent pupillary defect, acquired dyschromatopsia, visual loss and bilateral prechiasmatic field defect). * Exposure with a temporal relationship of less than two weeks to a known toxicant for the function of the optic nerve. * Up to 21 days from symptom onset. * Informed consent signature. Exclusion Criteria: * History of previous optic neuropathy. * History of additional ophthalmological or neurological pathology that has caused permanent visual loss. * History of previous treatment with intravenous methylprednisolone or some other experimental treatment since the onset of symptoms. * Poorly controlled diabetes mellitus. * Poorly controlled systemic arterial hypertension. * Hemoglobin \>16 mg/dL * Patients with a history of thromboembolic event. * Patients with a history of coronary heart disease, myocardial infarction or cerebral vascular event. * Pregnancy or lactation.